Abcam, ab277512, Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1]

Size: 100µg / 1mg
Human Recombinant Monoclonal SPIKE antibody. Suitable for I-ELISA and reacts with Recombinant full length protein - SARS-CoV-2 samples. Cited in 2 publications.
Key facts
Host species:Human,
Clonality:Monoclonal,
Clone number:CV1,
Isotype:IgG1,
Light chain type:lambda,
Carrier free:No,
Applications:I-ELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
CV1 antibody cross-reacts with SARS-CoV-2 Spike Ectodomain (including S1 domain), but not with SARS-CoV-2 Spike RBD. CV1 does not demonstrate significant neutralising ability in in-direct ELISA, measuring competitive binding of CV1 to SARS-CoV-2 Spike RBD in the presence of human ACE2
Please note: This antibody was first isolated as an IgG1 lambda subclass. During the cloning process for the recombinant product, this was converted to an IgG1 kappa subclass, although the light chain variable region is still of the lambda subclass.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Preservative: 0.02% Proclin 300Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The SARS-CoV-2 Spike Ectodomain often referred to simply as the spike protein is a critical component of the virus that enables entry into host cells. This glycoprotein is about 180 kDa and is prominently expressed on the viral surface. The spike protein is marked by significant regions including the S1 and S2 subunits which facilitate the binding and fusion processes necessary for viral entry into human cells. Variants like the D614G and notable mutations such as H69 deletion or D80A affect its structure. The spike protein is central to vaccine design due to its role in mediating infection.
Biological function summary
The spike protein is critical for the interaction with the host angiotensin-converting enzyme 2 (ACE2) serving as an important component in the viral entry into human cells. It forms a trimeric complex important for mediating the fusion of the viral membrane with the host cell's membrane. Structural changes such as deletions in the HV69-70 region or mutations like D80A can impact the protein's functionality and viral virulence. Therefore understanding these mutations has implications for infection control efforts.
Pathways
The spike protein plays a central role in the viral invasion pathway that starts with the recognition of the ACE2 receptor on the host cell. This pathway integrates the spike protein's functionality with other viral and host proteins leading to cell entry and subsequent viral replication. The renin-angiotensin system (RAS) is closely related given the ACE2 receptor's involvement in this physiological pathway highlighting the importance of these interactions in both viral pathology and host response.
The spike protein is instrumental in the pathogenesis of COVID-19 and related respiratory disorders. Its interaction with ACE2 is central in determining the infection's severity and transmission potential. Additionally the spike protein's structural changes such as HV69-70 deletions or D80A mutations can alter the disease manifestation by affecting how the immune system recognizes the virus. This structural variability potentially impacts vaccine efficacy and therapeutic antibody effectiveness complicating disease management and treatment strategies.